Search

Your search keyword '"Koenecke, Christian"' showing total 291 results
Start Over Author "Koenecke, Christian" Publication Year Range Last 50 years Language english
291 results on '"Koenecke, Christian"'

1. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?

Author

Penack, Olaf, Abouqateb, Mouad, Peczynski, Christophe, Boreland, William, Kröger, Nicolaus, Stelljes, Matthias, Gedde-Dahl, Tobias, Blau, Igor Wolfgang, Schroeder, Thomas, Salmenniemi, Urpu, Kulagin, Alexander, Peffault de Latour, Régis, Mielke, Stephan, Zeiser, Robert, Moiseev, Ivan, Schoemans, Hélène, Koenecke, Christian, and Peric, Zinaida

Published
2024
Full Text
View/download PDF

2. ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party

Author

Penack, Olaf, Peczynski, Christophe, Boreland, William, Lemaitre, Jessica, Reinhardt, H. Christian, Afanasyeva, Ksenia, Avenoso, Daniele, Holderried, Tobias A. W., Kornblit, Brian Thomas, Gavriilaki, Eleni, Martinez, Carmen, Chiusolo, Patrizia, Mico, Maria Caterina, Dagunet, Elisabeth, Wichert, Stina, Ozdogu, Hakan, Piekarska, Agnieszka, Kinsella, Francesca, Basak, Grzegorz W., Schoemans, Hélène, Koenecke, Christian, Moiseev, Ivan, and Peric, Zinaida

Published
2024
Full Text
View/download PDF

3. The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation: a study from the EBMT Transplant Complications Working Party

Author

Gjærde, Lars Klingen, Ruutu, Tapani, Peczynski, Christophe, Boreland, William, Kröger, Nicolaus, Blaise, Didier, Schroeder, Thomas, Peffault de Latour, Régis, Gedde-Dahl, Tobias, Kulagin, Aleksandr, Sengeløv, Henrik, Yakoub-Agha, Ibrahim, Finke, Jürgen, Eder, Matthias, Basak, Grzegorz, Moiseev, Ivan, Schoemans, Hélène, Koenecke, Christian, Penack, Olaf, and Perić, Zinaida

Published
2024
Full Text
View/download PDF

4. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Author

Mackensen, Andreas, Haanen, John B.A.G., Koenecke, Christian, Alsdorf, Winfried, Wagner-Drouet, Eva, Borchmann, Peter, Heudobler, Daniel, Ferstl, Barbara, Klobuch, Sebastian, Bokemeyer, Carsten, Desuki, Alexander, Lüke, Florian, Kutsch, Nadine, Müller, Fabian, Smit, Eveline, Hillemanns, Peter, Karagiannis, Panagiotis, Wiegert, Erol, He, Ying, Ho, Thang, Kang-Fortner, Qing, Schlitter, Anna Melissa, Schulz-Eying, Catrine, Finlayson, Andrew, Flemmig, Carina, Kühlcke, Klaus, Preußner, Liane, Rengstl, Benjamin, Türeci, Özlem, and Şahin, Uğur

Published
2023
Full Text
View/download PDF

5. Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study

Author

Ruutu, Tapani, Peczynski, Christophe, Houhou, Mohamed, Polge, Emmanuelle, Mohty, Mohamad, Kröger, Nicolaus, Moiseev, Ivan, Penack, Olaf, Salooja, Nina, Schoemans, Hélène, Duarte, Rafael F., Schroeder, Thomas, Passweg, Jakob, Wulf, Gerald G., Ganser, Arnold, Sica, Simona, Arat, Mutlu, Salmenniemi, Urpu, Broers, Annoek E. C., Bourhis, Jean Henri, Rambaldi, Alessandro, Maertens, Johan, Halaburda, Kazimierz, Zuckerman, Tsila, Labussière-Wallet, Hélène, Basak, Grzegorz, Koenecke, Christian, and Perić, Zinaida

Published
2023
Full Text
View/download PDF

6. Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT

Author

Gjærde, Lars Klingen, Peczynski, Christophe, Polge, Emmanuelle, Kröger, Nicolaus, de Latour, Régis Peffault, Finke, Jürgen, Holler, Ernst, Blaise, Didier, Helbig, Grzegorz, Salmenniemi, Urpu, Potter, Victoria, Bunjes, Donald, Erzsebet, Lazar, Penack, Olaf, Schoemans, Hélène, Koenecke, Christian, Basak, Grzegorz W., and Perić, Zinaida

Published
2023
Full Text
View/download PDF

7. The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease

Author

Stadler, Michael, Hambach, Lothar, Dammann, Elke, Diedrich, Helmut, Kamal, Haytham, Hamwi, Iyas, Schultze-Florey, Christian, Varvenne, Michael, Ehrlich, Steve, Buchholz, Stefanie, Koenecke, Christian, Beutel, Gernot, Weissinger, Eva M., Krauter, Jürgen, Eder, Matthias, Hertenstein, Bernd, and Ganser, Arnold

Published
2023
Full Text
View/download PDF

8. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

Author

Dreger, Peter, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian, Ayuk, Francis, Wagner, Eva, Wulf, Gerald, Marks, Reinhardt, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian, von Bonin, Malte, Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D., Vucinic, Vladan, Mougiakakos, Dimitrios, Topp, Max, Schroers, Roland, Wolff, Daniel, Thomas, Simone, Kröger, Nicolaus, and Bethge, Wolfgang A.

Published
2023
Full Text
View/download PDF

10. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany

Author

Bader, Peter, Rossig, Claudia, Hutter, Martin, Ayuk, Francis Ayuketang, Baldus, Claudia D., Bücklein, Veit L., Bonig, Halvard, Cario, Gunnar, Einsele, Hermann, Holtick, Udo, Koenecke, Christian, Bakhtiar, Shahrzad, Künkele, Annette, Meisel, Roland, Müller, Fabian, Müller, Ingo, Penack, Olaf, Rettinger, Eva, Sauer, Martin G., Schlegel, Paul-Gerhardt, Soerensen, Jan, von Stackelberg, Arend, Strahm, Brigitte, Hauer, Julia, Feuchtinger, Tobias, and Jarisch, Andrea

Published
2023
Full Text
View/download PDF

11. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial

Author

Zimmermann, Heiner, Koenecke, Christian, Dreyling, Martin H., Pott, Christiane, Dührsen, Ulrich, Hahn, Dennis, Meidenbauer, Norbert, Hauser, Ingeborg A., Rummel, Mathias J., Wolf, Dominik, Heuser, Michael, Schmidt, Christian, Schlattmann, Peter, Ritgen, Matthias, Siebert, Reiner, Oschlies, Ilske, Anagnostopoulos, Ioannis, and Trappe, Ralf U.

Published
2022
Full Text
View/download PDF

12. Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT

Author

Koenecke, Christian, Eikema, Dirk-Jan, Hazelaar, Sheree, Schroeder, Thomas, Potter, Victoria, Kröger, Nicolaus, Bornhäuser, Martin, Finke, Jürgen, Platzbecker, Uwe, Radujkovic, Aleksandar, Ganser, Arnold, Salmenniem, Urpu, Blaise, Didier, Kobbe, Guido, Meijer, Ellen, Friis, Lone, Maertens, Johan, Caballero, Dolores, Cornelissen, Jan J., Olivieri, Attilio, Gulsum, Ozet, Hayden, Patrick J., Onida, Francesco, Robin, Marie, and Yakoub-Agha, Ibrahim

Published
2022
Full Text
View/download PDF

13. Practice patterns in chronic graft-versus-host disease patient management and patient reported outcome measures across the EBMT allogeneic transplantation network

Author

Perovic, Vladimir, Sabol, Ivan, Grce, Magdalena, Inngjerdingen, Marit, Pulanic, Drazen, Peric, Zinaida, Peczynski, Christophe, Polge, Emmanuelle, Koenecke, Christian, Dickinson, Anne, Greinix, Hildegard, Basak, Grzegorz, Penack, Olaf, Scherwath, Angela, Barata, Anna, Olivieri, Attilio, Lawitschka, Anita, Mensah-Glanowska, Patrycja, Andrikovics, Hajnalka, Schoemans, Helene, and Wolff, Daniel

Published
2022
Full Text
View/download PDF

17. HEV infection in stem cell transplant recipients—retrospective study of EBMT Infectious Diseases Working Party

Author

Mikulska, Malgorzata, Penack, Olaf, Wendel, Lotus, Knelange, Nina, Cornelissen, Jan J., Blijlevens, Nicole, Passweg, Jakob, Kroger, Nicolaus, Bruns, Anke, Koenecke, Christian, Bierings, Marc, Piñana, José Luis, Labussiere-Wallet, Helene, Ghesquieres, Herve, Diaz, Miguel Angel, Sampol, Antonia, Averbuch, Diana, de la Camara, Rafael, and Styczynski, Jan

Published
2022
Full Text
View/download PDF

18. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Author

Bethge, Wolfgang A., Martus, Peter, Schmitt, Michael, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian, Ayuk, Francis, Wagner-Drouet, Eva Marie, Wulf, Gerald G., Marks, Reinhard, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian, von Bonin, Malte, Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D., Vucinic, Vladan, Mougiakakos, Dimitrios, Topp, Max, Fante, Matthias A., Schroers, Roland, Bayir, Lale, Borchmann, Peter, Buecklein, Veit, Hasenkamp, Justin, Hanoun, Christine, Thomas, Simone, Beelen, Dietrich W., Lengerke, Claudia, Kroeger, Nicolaus, and Dreger, Peter

Published
2022
Full Text
View/download PDF

19. Influence of pretransplant inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis study from the Transplant Complications Working Party (TCWP) of the EBMT

Author

Peric, Zinaida, Peczynski, Christophe, Polge, Emmanuelle, Kröger, Nicolaus, Sengeloev, Henrik, Radujkovic, Aleksandar, Helbig, Grzegorz, Russell, Nigel, Bunjes, Donald, Socié, Gerard, Potter, Victoria, Beelen, Dietrich, Crawley, Charles, Bloor, Adrian, Finke, Jürgen, Schoemans, Helene, Penack, Olaf, Snowden, John A., Koenecke, Christian, and Basak, Grzegorz W.

Published
2021
Full Text
View/download PDF

20. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Author

Vincent, Laure, Gras, Luuk, Ceballos, Patrice, Finke, Jürgen, Passweg, Jakob, Harel, Stéphanie, Rosinol, Laura, Minnema, Monique, Teipel, Raphael, van Doesum, Jaap, Hänel, Mathias, Lenain, Pascal, Botella-Garcia, Carmen, Koenecke, Christian, Ducastelle, Sophie, Sanz, Jaime, Schroyens, Wilfried, Zuckerman, Tsila, Monaco, Federico, Koster, Linda, de Wreede, Liesbeth, Hayden, Patrick J., Schönland, Stefan, Yakoub-Agha, Ibrahim, and Beksac, Meral

Published
2022
Full Text
View/download PDF

23. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Author

Liebers, Nora, Duell, Johannes, Fitzgerald, Donnacha, Kerkhoff, Andrea, Noerenberg, Daniel, Kaebisch, Eva, Acker, Fabian, Fuhrmann, Stephan, Leng, Corinna, Welslau, Manfred, Chemnitz, Jens, Middeke, Jan-Moritz, Weber, Thomas, Holtick, Udo, Trappe, Ralf, Pfannes, Roald, Liersch, Ruediger, Spoer, Christian, Fuxius, Stefan, Gebauer, Niklas, Caillé, Léandra, Geer, Thomas, Koenecke, Christian, Keller, Ulrich, Claus, Rainer, Mougiakakos, Dimitrios, Mayer, Stephanie, Huettmann, Andreas, Pott, Christiane, Trummer, Arne, Wulf, Gerald, Brunnberg, Uta, Bullinger, Lars, Hess, Georg, Mueller-Tidow, Carsten, Glass, Bertram, Lenz, Georg, Dreger, Peter, and Dietrich, Sascha

Published
2021
Full Text
View/download PDF

24. Immunization against poly- N -acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity

Author

Hülsdünker, Jan, Thomas, Oliver S., Haring, Eileen, Unger, Susanne, Núñez, Nicolás Gonzalo, Tugues, Sonia, Gao, Zhan, Duquesne, Sandra, Cywes-Bentley, Colette, Oyardi, Ozlem, Kirschnek, Susanne, Schmitt-Graeff, Annette, Pabst, Oliver, Koenecke, Christian, Duyster, Justus, Apostolova, Petya, Blaser, Martin J., Becher, Burkhard, Pier, Gerald B., Häcker, Georg, and Zeiser, Robert

Published
2019

28. Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.

Author

Zeremski, Vanja, Adolph, Louisa, Beer, Sina, Berisha, Mirjeta, Jacobs, Benedikt, Kahl, Christoph, Koenecke, Christian, Kropf, Siegfried, Panse, Jens, Petersen, Judith, Schmidt‐Hieber, Martin, Schneider, Jessica, Vucinic, Vladan, Walter, Jeanette, Weigert, Oliver, Witte, Hanno M., and Mougiakakos, Dimitrios

Subjects
STEM cell transplantation, DISEASE risk factors, LYMPHOMAS, CENTRAL nervous system, PROGRESSION-free survival
Abstract

Objectives: Treatment intensification (including consolidative high‐dose chemotherapy with autologous stem cell transplantation [HDT‐ASCT]) significantly improved outcome in primary central nervous system lymphoma (PCNSL) patients. Methods: We conducted a multicenter, retrospective analysis of newly diagnosed PCNSL patients, treated with intensified treatment regimens. The following scores were evaluated in terms of overall survival (OS) and progression‐free survival (PFS): Memorial Sloan‐Kettering Cancer Center (MSKCC), International Extranodal Lymphoma Study Group (IELSG), and three‐factor (3F) prognostic score. Further, all scores were comparatively investigated for model quality and concordance. Results: Altogether, 174 PCNSL patients were included. One hundred and five patients (60.3%) underwent HDT‐ASCT. Two‐year OS and 2‐year PFS for the entire population were 73.3% and 48.5%, respectively. The MSKCC (p =.003) and 3F score (p <.001), but not the IELSG score (p =.06), had the discriminatory power to identify different risk groups for OS. In regard to concordance, the 3F score (C‐index [0.71]) outperformed both the MSKCC (C‐index [0.64]) and IELSG (C‐index [0.53]) score. Moreover, the superiority of the 3F score was shown for PFS, successfully stratifying patients in three risk groups, which also resulted in the highest C‐index (0.66). Conclusion: The comparative analysis of established PCNSL risk scores affirm the clinical utility of the 3F score stratifying the widest prognostic spectrum among PCNSL patients treated with intensified treatment approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.

Author

Penack, Olaf, Abouqateb, Mouad, Peczynski, Christophe, Boreland, William, Gülbas, Zafer, Gedde-Dahl, Tobias, Castilla-Llorente, Cristina, Kröger, Nicolaus, Eder, Mathias, Rambaldi, Alessandro, Bonifazi, Francesca, Blau, Igor Wolfgang, Stelljes, Matthias, Dreger, Peter, Moiseev, Ivan, Schoemans, Hélène, Koenecke, Christian, and Peric, Zinaida

Subjects
STEM cell transplantation, GRAFT versus host disease, PREVENTIVE medicine, OVERALL survival, PROGRESSION-free survival
Abstract

There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it is standard practice to use rabbit anti-thymocyte globulin (rATG) to reduce the high NRM and GVHD risks after MMUD alloSCT. As an alternative to rATG, post-transplantation Cyclophosphamide (PTCy) is in increasing clinical use. It is currently impossible to give general recommendations regarding preference for one method over another since comparative evidence from larger data sets is lacking. To improve the evidence base, we analyzed the outcome of rATG vs. PTCy prophylaxis in adult patients with hematologic malignancies undergoing first peripheral blood alloSCT from MMUD (9/10 antigen match) between Jan 2018 and June 2021 in the database of the European Society for Blood and Marrow Transplantation (EBMT). We performed multivariate analyses using the Cox proportional-hazards regression model. We included 2123 patients in the final analyses (PTCy, n = 583; rATG, n = 1540). p values and hazard ratios (HR) presented here are multivariate outcomes. Two years after alloSCT we found a lower NRM in the PTCy group of 18% vs. 24.9% in the rATG group; p = 0.028, HR 0.74. Overall survival in the PTCy cohort was higher with 65.7% vs. 55.7% in the rATG cohort; p < 0.001, HR 0.77. Progression-free survival was also better in the PTCy patients with 59.1% vs. 48.8% when using rATG; p = 0.001, 0.78. The incidences of chronic GVHD and acute GVHD were not significantly different between the groups. We found significantly lower NRM as well as higher survival in recipients of peripheral blood alloSCTs from MMUD receiving PTCy as compared to rATG. The results of the current analysis suggest an added value of PTCy as GVHD prophylaxis in MMUD alloSCT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Management of Patients Undergoing CAR-T Cell Therapy in Germany.

Author

Penack, Olaf, Dreger, Peter, Ajib, Salem, Ayuk, Francis, Baermann, Ben-Niklas, Bug, Gesine, Kriege, Oliver, Jentzsch, Madlen, Kobbe, Guido, Koenecke, Christian, Lutz, Mathias, Martin, Sonja, Schlegel, Paul-Gerhard, Schroers, Roland, von Tresckow, Bastian, Vucinic, Vladan, Subklewe, Marion, Bethge, Wolfgang, and Wolff, Daniel

Subjects
STEM cell transplantation, CELLULAR therapy, HEMATOPOIETIC stem cell transplantation, CELL transplantation, CYTOKINE release syndrome, NON-Hodgkin's lymphoma
Abstract

Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin's lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. Methods: To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. Results: We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no – or low quality – clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. Conclusion: The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time.

Author

Odak, Ivan, Bayir, Lâle M., Riemann, Lennart, Sikora, Ruth, Schneider, Jessica, Yankai Xiao, Möhn, Nora, Skripuletz, Thomas, Beutel, Gernot, Eder, Matthias, Ganser, Arnold, Förster, Reinhold, Schultze-Florey, Christian R., and Koenecke, Christian

Subjects
CD19 antigen, T cells, IMMUNOPHENOTYPING, DIFFUSE large B-cell lymphomas
Abstract

Variability or stability might have an impact on treatment success and toxicity of CD19 CAR T-cells. We conducted a prospective observational study of 12 patients treated with Tisagenlecleucel for CD19+ B-cell malignancies. Using a 31-color spectral flow cytometry panel, we analyzed differentiation stages and exhaustion markers of CAR T-cell subsets prior to CAR T-cell infusion and longitudinally during 6 months of follow-up. The majority of activation markers on CAR T-cells showed stable expression patterns over time and were not associated with response to therapy or toxicity. Unsupervised cluster analysis revealed an immune signature of CAR T-cell products associated with the development of immune cell-associated neurotoxicity syndrome. Warranting validation in an independent patient cohort, in-depth phenotyping of CAR T-cell products as well as longitudinal monitoring post cell transfer might become a valuable tool to increase efficacy and safety of CAR T-cell therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT

Author

Ruutu, Tapani, van der Werf, Steffie, van Biezen, Anja, Backman, Janne T., Peczynski, Christophe, Kröger, Nicolaus, Mohty, Mohamad, Nagler, Arnon, Montoto, Silvia, Langebrake, Claudia, Niederwieser, Dietger, Peric, Zinaida, Koenecke, Christian, Duarte, Rafael F., and Basak, Grzegorz

Published
2019
Full Text
View/download PDF

33. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

Author

Thol, Felicitas, Gabdoulline, Razif, Liebich, Alessandro, Klement, Piroska, Schiller, Johannes, Kandziora, Christian, Hambach, Lothar, Stadler, Michael, Koenecke, Christian, Flintrop, Madita, Pankratz, Mira, Wichmann, Martin, Neziri, Blerina, Büttner, Konstantin, Heida, Bennet, Klesse, Sabrina, Chaturvedi, Anuhar, Kloos, Arnold, Göhring, Gudrun, Schlegelberger, Brigitte, Gaidzik, Verena I., Bullinger, Lars, Fiedler, Walter, Heim, Albert, Hamwi, Iyas, Eder, Matthias, Krauter, Jürgen, Schlenk, Richard F., Paschka, Peter, Döhner, Konstanze, Döhner, Hartmut, Ganser, Arnold, and Heuser, Michael

Published
2018
Full Text
View/download PDF

34. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Garderet, Laurent, Iacobelli, Simona, Koster, Linda, Goldschmidt, Hartmut, Johansson, Jan-Erik, Bourhis, Jean Henri, Krejci, Marta, Leleu, Xavier, Potter, Michael, Blaise, Didier, Koenecke, Christian, Peschel, Christian, Radocha, Jakub, Metzner, Bernd, Lenain, Pascal, Schäfer-Eckart, Kerstin, Pohlreich, David, Grasso, Mariella, Caillot, Denis, Einsele, Herman, Ladetto, Marco, Schönland, Stefan, and Kröger, Nicolaus

Published
2018
Full Text
View/download PDF

35. Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients

Author

Lueck, Catherina, Stadler, Michael, Koenecke, Christian, Hoeper, Marius M., Dammann, Elke, Schneider, Andrea, and Kielstein, Jan T.

Subjects
Antithymocyte globulin -- Analysis, Hematopoietic stem cells -- Transplantation -- Analysis, Hospital patients -- Patient outcomes, Septic shock -- Patient outcomes, Acute respiratory distress syndrome -- Patient outcomes, Health care industry
Abstract

Purpose Intensive care unit (ICU) admission of allogeneic hematopoietic stem cell transplant (HSCT) recipients is associated with relatively poor outcome. Since longitudinal data on this topic remains scarce, we analyzed reasons for ICU admission as well as short- and long-term outcome of critically ill HSCT recipients. Methods A total of 942 consecutive adult patients were transplanted at Hannover Medical School from 2000 to 2013. Of those, 330 patients were at least admitted once to the ICU and included in this retrospective study. To analyze time-dependent improvements, we separately compared patient characteristics as well as reasons and outcome of ICU admission for the periods 2000-2006 and 2007-2013. Results The main reasons for ICU admission were acute respiratory failure (ARF) in 35%, severe sepsis/septic shock in 23%, and cardiac problems in 18%. ICU admission was clearly associated with shortened survival (p < 0.001), but survival of ICU patients after hospital discharge reached 44% up to 5 years and was comparable to that of non-ICU HSCT patients. When ICU admission periods were compared, patients were older (48 vs. 52 years; p < 0.005) and the percentage of ARF as leading cause for ICU admission decreased from 43% in the first to 30% in the second period. Over time ICU and hospital survival improved from 44 to 60% (p < 0.01) and from 26 to 43% (p < 0.01), respectively. The 1- and 3-year survival rate after ICU admission increased significantly from 14 to 32% and from 11 to 23% (p < 0.01). Conclusions Besides ARF and septic shock, cardiac events were especially a major reason for ICU admission. Both short- and long-term survival of critically ill HSCT patients has improved significantly in recent years, and survival of HSCT recipients discharged from hospital is not significantly affected by a former ICU stay., Author(s): Catherina Lueck [sup.1] [sup.5], Michael Stadler [sup.1], Christian Koenecke [sup.1], Marius M. Hoeper [sup.2], Elke Dammann [sup.1], Andrea Schneider [sup.3], Jan T. Kielstein [sup.4], Arnold Ganser [sup.1], Matthias Eder [...]

Published
2018
Full Text
View/download PDF

36. Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT

Author

Moiseev, Ivan S., Tsvetkova, Tatyana, Aljurf, Mahmoud, Alnounou, Randa M, Bogardt, Janet, Chalandon, Yves, Drokov, Mikhail Yu., Dvirnyk, Valentina, Faraci, Maura, Friis, Lone Smidstrup, Giglio, Fabio, Greinix, Hildegard T., Kornblit, Brian Thomas, Koelper, Christiane, Koenecke, Christian, Lewandowski, Krzysztof, Niederwieser, Dietger, Passweg, Jakob R., Peczynski, Christophe, Penack, Olaf, Peric, Zinaida, Piekarska, Agnieszka, Ronchi, Paola Erminia, Rovo, Alicia, Rzepecki, Piotr, Scuderi, Francesca, Sigrist, Daniel, Siitonen, Sanna M., Stoelzel, Friedrich, Sulek, Kazimierz, Tsakiris, Dimitrios A., Wilkowojska, Urszula, Duarte, Rafael F, Ruutu, Tapani, and Basak, Grzegorz W

Published
2019
Full Text
View/download PDF

37. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation

Author

Kröger, Nicolaus, Panagiota, Victoria, Badbaran, Anita, Zabelina, Tatjana, Triviai, Ioanna, Araujo Cruz, Michelle Maria, Shahswar, Rabia, Ayuk, Francis, Gehlhaar, Marten, Wolschke, Christine, Bollin, Robin, Walter, Carolin, Dugas, Martin, Wiehlmann, Lutz, Lehmann, Ulrich, Koenecke, Christian, Chaturvedi, Anuhar, Alchalby, Haefaa, Stadler, Michael, Eder, Matthias, Christopeit, Max, Göhring, Gudrun, Koenigsmann, Michael, Schlegelberger, Brigitte, Kreipe, Hans-Heinrich, Ganser, Arnold, Stocking, Carol, Fehse, Boris, Thol, Felicitas, and Heuser, Michael

Published
2017
Full Text
View/download PDF

38. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party.

Author

Penack, Olaf, Peczynski, Christophe, Koenecke, Christian, Polge, Emmanuelle, Sanderson, Robin, Yakoub-Agha, Ibrahim, Fegueux, Nathalie, Daskalakis, Michael, Collin, Matthew, Dreger, Peter, Kröger, Nicolaus, Schanz, Urs, Bloor, Adrian, Ganser, Arnold, Besley, Caroline, Wulf, Gerald G., Novak, Urban, Moiseev, Ivan, Schoemans, Hélène, and Basak, Grzegorz W.

Subjects
B cell lymphoma, STEM cell transplantation, CUTANEOUS T-cell lymphoma, CD19 antigen, CHIMERIC antigen receptors, T cells, DIFFUSE large B-cell lymphomas, LYMPHOMAS
Abstract

We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML.

Author

Teich, Katrin, Stadler, Michael, Gabdoulline, Razif, Kandarp, Jyoti, Wienecke, Clara, Heida, Bennet, Klement, Piroska, Büttner, Konstantin, Venturini, Letizia, Wichmann, Martin, Puppe, Wolfram, Schultze-Florey, Christian, Koenecke, Christian, Beutel, Gernot, Eder, Matthias, Ganser, Arnold, Heuser, Michael, and Thol, Felicitas

Subjects
BIOMARKERS, KRUSKAL-Wallis Test, STATISTICS, SEQUENCE analysis, MULTIVARIATE analysis, BIOINFORMATICS, SURVIVAL analysis (Biometry), KAPLAN-Meier estimator, CHI-squared test, DESCRIPTIVE statistics, RESEARCH funding, HEMATOPOIETIC stem cell transplantation, RED blood cell transfusion, DATA analysis software, OVERALL survival, PROPORTIONAL hazards models
Abstract

Simple Summary: Donor lymphocyte infusions (DLIs) are immune cells of the donor. They can potentially directly target leukemic cells. Thus, DLIs can be given to acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (alloHCT) in order to prevent or treat relapse. Measurable residual disease (MRD) describes very low levels of disease. Currently, it is still not well described how we can use MRD assessment for predicting response and outcome after DLI. This is a retrospective study looking at 76 AML patients receiving DLI treatment. MRD was evaluated prior to DLI treatment as well as 30 and 90 days after DLI. It was observed that within 90 days after DLI treatment, 73% of MRD+ patients converted to MRD−. Furthermore, MRD and remission status at the time of DLI were highly prognostic for the outcome (both for the relapse rate and also for relapse-free survival). Donor lymphocyte infusions (DLIs) can directly target leukemic cells through a graft-versus-leukemia effect and play a key role in the prevention and management of relapse after allogeneic hematopoietic cell transplantation (alloHCT). Predictors of response to DLIs are not well established. We evaluated measurable residual disease (MRD) before, 30 and 90 days after DLI treatment as biomarkers of response. MRD was assessed by next-generation sequencing in 76 DLI-treated acute myeloid leukemia patients. MRD status before DLI treatment was independently prognostic for event-free survival (EFS, p < 0.001) and overall survival (OS, p < 0.001). Within 90 days of DLI treatment, 73% of MRD+ patients converted to MRD− and 32% of patients without remission achieved remission. MRD status 90 days after DLI treatment was independently prognostic for the cumulative incidence of relapse (CIR, p = 0.011) and relapse-free survival (RFS, p = 0.001), but not for OS. To evaluate the role of DLI treatment in MRD− patients, 23 MRD− patients who received DLIs were compared with a control cohort of 68 MRD− patients not receiving DLIs. RFS (p = 0.23) and OS (p = 0.48) were similar between the two cohorts. In conclusion, MRD is prognostic before (EFS, OS) and after (CIR, RFS) DLI treatment and may help in the selection of patients who benefit most from DLIs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells

Author

Hammer, Quirin, Rückert, Timo, Borst, Eva Maria, Dunst, Josefine, Haubner, André, Durek, Pawel, Heinrich, Frederik, Gasparoni, Gilles, Babic, Marina, Tomic, Adriana, Pietra, Gabriella, Nienen, Mikalai, Blau, Igor Wolfgang, Hofmann, Jörg, Na, Il-Kang, Prinz, Immo, Koenecke, Christian, Hemmati, Philipp, Babel, Nina, Arnold, Renate, Walter, Jörn, Thurley, Kevin, Mashreghi, Mir-Farzin, Messerle, Martin, and Romagnani, Chiara

Published
2018
Full Text
View/download PDF

41. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation

Author

Heuser, Michael, Gabdoulline, Razif, Löffeld, Patrick, Dobbernack, Vera, Kreimeyer, Henriette, Pankratz, Mira, Flintrop, Madita, Liebich, Alessandro, Klesse, Sabrina, Panagiota, Victoria, Stadler, Michael, Wichmann, Martin, Shahswar, Rabia, Platzbecker, Uwe, Thiede, Christian, Schroeder, Thomas, Kobbe, Guido, Geffers, Robert, Schlegelberger, Brigitte, Göhring, Gudrun, Kreipe, Hans-Heinrich, Germing, Ulrich, Ganser, Arnold, Kröger, Nicolaus, Koenecke, Christian, and Thol, Felicitas

Published
2017
Full Text
View/download PDF

43. Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party

Author

Robin, Marie, Ruggeri, Annalisa, Labopin, Myriam, Niederwieser, Dietger, Tabrizi, Reza, Sanz, Guillermo, Bourhis, Jean-Henri, van Biezen, Anja, Koenecke, Christian, Blaise, Didier, Tischer, Johanna, Craddock, Charles, Maillard, Natacha, Mohty, Mohamad, Russel, Nigel, Schetelig, Johannes, Finke, Jürgen, Gluckman, Eliane, de Witte, Theo M., Rocha, Vanderson, and Kroger, Nicolaus

Published
2015
Full Text
View/download PDF

44. Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party

Author

Penack, Olaf, Peczynski, Christophe, Koenecke, Christian, Polge, Emmanuelle, Potter, Victoria, Fegueux, Nathalie, Daskalakis, Michael, Kröger, Nicolaus, Dreger, Peter, Besley, Caroline, Schanz, Urs, Bloor, Adrian, Ganser, Arnold, Forcade, Edouard, Corral, Lucía López, Passweg, Jakob, Novak, Urban, Moiseev, Ivan, Schoemans, Helene, Basak, Grzegorz W., Chabannon, Christian, Sureda, Anna, Averbuch, Diana, Glass, Bertram, De La Camara, Rafael, and Peric, Zinaida

Published
2022
Full Text
View/download PDF

45. Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Author

Penack, Olaf, Peczynski, Christophe, Koenecke, Christian, Polge, Emmanuelle, Potter, Victoria, Yakoub-Agha, Ibrahim, Fegueux, Nathalie, Daskalakis, Michael, Collin, Matthew P., Dreger, Peter, Kröger, Nicolaus, Schanz, Urs, Bloor, Adrian, Ganser, Arnold, Besley, Caroline, Wulf, Gerald, Novak, Urban, Moiseev, Ivan, Schoemans, Helene, Basak, Grzegorz W, Chabannon, Christian, Sureda, Anna, Glass, Bertram, and Peric, Zinaida

Published
2022
Full Text
View/download PDF

46. CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany

Author

Bader, Peter, Rossig, Claudia, Hutter, Martin, Ayuk, Francis A., Baldus, Claudia D., Buecklein, Veit L, Bonig, Halvard, Cario, Gunnar, Einsele, Hermann, Holtick, Udo, Koenecke, Christian, Künkele, Annette, Meisel, Roland, Mueller, Fabian, Müller, Ingo, Penack, Olaf, Rettinger, Eva, Sauer, Martin G., Schlegel, Paul-Gerhardt, Soerensen, Jan, von Stackelberg, Arend, Feuchtinger, Tobias, and Jarisch, Andrea

Published
2022
Full Text
View/download PDF

47. Publisher Correction: Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection

Author

Ravens, Sarina, Schultze-Florey, Christian, Raha, Solaiman, Sandrock, Inga, Drenker, Melanie, Oberdörfer, Linda, Reinhardt, Annika, Ravens, Inga, Beck, Maleen, Geffers, Robert, von Kaisenberg, Constantin, Heuser, Michael, Thol, Felicitas, Ganser, Arnold, Förster, Reinhold, Koenecke, Christian, and Prinz, Immo

Published
2018
Full Text
View/download PDF

49. Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis

Author

Hess, Georg, Vucinic, Vladan, Rejeski, Kai, Aydilek, Enver, Simon, Linda, Penack, Olaf, Koenecke, Christian, von Bonin, Malte, von Tresckow, Bastian, Fehr, Martin, Pott, Christiane, Stilgenbauer, Stephan, Leng, Corinna, Schroers, Roland, Duell, Johannes, Marks, Reinhard, Mueller, Fabian, Brunnberg, Uta, Kerkhoff, Andrea, Ohler, Anke, Wagner Drouet, Eva-Maria, Schmidtmann, Irene, Theobald, Matthias, Dreyling, Martin, and Dreger, Peter

Published
2023
Full Text
View/download PDF

50. Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Author

Orti, Guillermo, Peczynski, Christophe, Koenecke, Christian, Boreland, William, O'Reilly, Maeve, Bornhäuser, Martin, Balduzzi, Adriana, Besley, Caroline, Kalwak, Krzysztof, Ryhanen, Samppa, Sr., Güngör, Tayfun, Wynn, Robert F., Bader, Peter, Mielke, Stephan, Blaise, Didier, Amrolia, Persis, Yakoub-Agha, Ibrahim, Calkoen, Friso G. J., Schubert, Maria-Luisa, Potter, Victoria, Holter, Wolfgang, Kröger, Nicolaus, Kwon, Mi, Sengeloev, Henrik, Schoemans, Helene, Moiseev, Ivan Sergeevich, Penack, Olaf, and Peric, Zinaida

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results